Gastric ulcerogenic and healing impairment actions of Alendronate, a Nitrogen- containing bisphosphonate - prophylactic effects of Rebamipide

Current Pharmaceutical Design

Volumn 17, Issue 16, 2011, Pages 1602-1611

  Takeuchi, Koji ^a   Kato, Shinichi ^a   Amagase, Kikuko ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Alendronate; Bisphosphonate; Gastric ulcerogenic action; Healing impairment action; Rebamipide

Indexed keywords

ALENDRONIC ACID; BASIC FIBROBLAST GROWTH FACTOR; CYCLOOXYGENASE 2; INDOMETACIN; REBAMIPIDE; VASCULOTROPIN;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME SYNTHESIS; HEALING IMPAIRMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; REFEEDING; STOMACH ANTRUM; STOMACH ULCER; VASCULARIZATION;

ALANINE; ALENDRONATE; ANIMALS; ANTI-ULCER AGENTS; BONE DENSITY CONSERVATION AGENTS; HUMANS; QUINOLONES; STOMACH ULCER; WOUND HEALING;

EID: 79959979239     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796196927     Document Type: Article

References (50)

1. Lowe CE, Depew TW, Vanner SJ, Paterson WG. Meddings JB. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000; 95: 634-40.
2. Iseri SO, Sener G, Yuksel M, et al. Ghrelin against alendronateinduced gastric damage in rats. J Endocrinol 2005; 187: 399-406.
3. Blank MA, Ems BL, Gibson GW, Myers WR, Berman SK, Phipps RJ, Smith PN. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997; 42: 281-8.
4. Wallace JL, Dicay M, McKnight W, Bastaki S, Blank MA. Nbisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Aliment Pharmacol Ther 1999; 13: 1675-82.
5. Russell RG, croucher PI, Roger MJ. Bisphosphonates: Pharmacology, mechanism of action and clinical uses. Osteoporosis Int 1999; 9: S66-80.
6. Lichtenberger LM, Romeo JJ, Gibson GW, Blank MA. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 2000; 45: 1792-801.
7. Luckman SP, Hughes DE, Coxon EP, Graham R, Russell G, Rogers MJ. Nitrogen- containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding protein, including rats. J Bone Miner Res 1998; 13: 581-9.
8. Marshall JK, Rainsford KD, James C, Hunt RH. A randomized controlled trials to assess alendronate-associated injury of the gastrointestinal tract. Aliment Pharmacol Ther 2000; 14: 1451-7.
9. Kanatsu K, Aihara E, Okayama M, Kato S, Takeuchi K. Mucosal irritative and healing impairment action of risedronate in rat stomachs: Comparison with alendronate. J Gastroenterol Hepatol 2004; 19: 512-20.
10. Ohashi Y, Aihara E, Takasuka H, Takahashi K, Takeuchi K. Antral ulcers induced by alendronate, a nitrogen-containing bisphosphonate, in rat stomachs: Prophylactic effect of rebamipide. J Physiol Pharmacol 2009; 60: 85-93.
11. Elliot SN, McKnight W, Davies NM, MacNaughton WK, Wallace JL. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci 1998; 62: 77-91.
12. Amagase K, Hayashi S, Nishikawa K, Aihara E, Takeuchi K. Impairment of gastric ulcer healing by alendronate, a nitrogencontaining bisphosphonate, in rats. Dig Dis Sci 2007; 52: 1879-89.
13. Aihara E, Hayashi S, Amagase K, Kato S, Takeuchi K. Prophylactic effect of rebamipide against the irritative and healing impairment actions of alendronate in rat stomachs. Inflammopharmacology 2007; 15: 196-202.
14. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosl protection by OPC-12759, a novel antiulcer compound in the rat. Eur J Pharmacol 1987; 142: 23-9.
15. Yamasaki K, Ishiyama H, Imaizumi T, Kanbe T, Yabuuchi Y. Effect of OPC-12795, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric seretion. Jpn J Pharmacol 1989; 49: 441-8.
16. Watanabe S, Wang XE, Hirose M, et al. Rebamipide prevented delay of wound repair induced by hydrogen peroxide and suppressed apoptosis of gastric epithelial cells in vitro. Dig Dis Sci 1998; 43 (Suppl): 107S-12S.
17. Sakurai K, Osaka T, Yamasaki K. Rebamipide reduces recurrence of experimental gastric ulcers: role of free radicals and neutrophils. Dig Dis Sci 2005; 50 (Suppl): S90-6.
18. Kim H, Seo JY, Kim KH. Inhibition of lipid peroxidation, NFkappaB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 2000; 45: 621-8.
19. Hiratsuka T, Futagami S, Shindo T, et al. Rebamipide reduces indomethacin- induced gastric injury in mice via down-regulation of ICAM-1 expression. Dig Dis Sci 2005; 50 (Suppl): S84-9.
20. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 1993; 38: 1441-9.
21. Ishihara, K, Komuro Y, Nishiyama N, et al. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittel-forschung 1992; 42: 1462-6.
22. Yamamoto O, Okada M, Okabe S. Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Dig Dis Sci 1984; 29: 394-401.
23. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: Current knowledge and proposed mechanisms. Am J Physiol 1983; 245: G601-23.
24. Takeeda M, Hayashi Y, Yamato M, Murakami M, Takeuchi K. Roles of endogenous prostaglandins and cyclooxygenase isozymes in mucosal defense of inflamed rat stomach. J Physiol Pharmacol 2003; 55: 193-205.
25. Takeuchi K, Furukawa O, Nishiwaki H, Okabe S. 16,16-dimethyl prostaglandin E2 aggravates gastric mucosal injury induced by histamine in rats: possible role of the increased mucosal vascular permeability. Gastroenterology 1987; 93: 1276-86.
26. Hase S, Yokota A, Nakagiri A, Takeuchi K. Prostaglandin E2 aggravates gastric mucosal injury induced by histamine in rats through EP1 receptors. Life Sci 2003; 74: 629-41.
27. Yamato M, Nagahama K, Kotani T, Kato S, Takeuchi K. Biphasic effect of prostaglandin E2 on a rat model of esophagitis mediated by EP1 receptors: Relation to pepsin secretion. Digestion 2005; 72: 109-18.
28. Satoh H, Guth PH. Role of gastric acid and prostaglandins in the formation of gastric antral ulcers produced by indomethacin in the rat. Prostaglandins 1981; 21 (Suppl): 131-7.
29. Satoh H, Guth PH, Grossman MI. Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology 1982; 83: 210-5.
30. Chen SH, Pan S, Okita K, Takemoto T. Role of superoxide dismutase in mechanism of diethyldithiocarbamate-induced gastric antral ulcer in rats: Protective effect of prostaglandin, cimetidine and pirenzepine. J Gastroenterol Hepatol 1993; 8: 457-61.
31. Ogino K, Hobara T, Ishiyama H, et al. Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate- induced antral gastric ulcers in rats. Eur J Pharmacol 1992; 212: 9-13.
32. Perry MA, Wadhwa S, Parks DA, Pickard W, Granger DN. Role of oxygen radicals in ischemia-induced leasions in the cat stomach. Gastroenterology 1986; 90: 362-7.
33. Loguercio C, Taranto D, Beneduce F, et al. Glutathione prevents ethanol induced gastric mucosal damage and depletion of sulfhydryl compounds in humans. Gut 1993; 34: 161-5.
34. Oka S, Ogino K, Hobara T, et al. Effects of various mucosal protective drugs on diethyl dithiocarbamate-induced antral ulcer in rats. Eur J Pharmacol 1991; 197: 99-102.
35. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387-97.
36. Brzozowski T, Konturek PC, Konturek SJ. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 2001; 53: 343-53.
37. Hatazawa R, Tanaka A, Tanigami M, Amagase K, Kato S, Ashida Y, Takeuchi K. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol 2007; 293: G788-97.
38. Halter F, Barbezat GO, Van Hoorn-Hickman R, Van Hoorn WA. Healing dynamics of traumatic gastric mucosal defects in normal and hyperacid stomach. Dig Dis Sci 1980; 25: 916-20.
39. Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997; 42: 281-8.
40. Tarnawski A. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50: S24-33.
41. Tarnawski A. Cellular mechanisms of gastric ulcer healing. In the stomach. W Domschke, SJ Konturek (eds). Berlin New York, Springer, 1993, pp 177-92.
42. Tarnawski AS, Jones MK. The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol 1998; 27: S12-20.
43. Bornfeldt KE, Raines EW, Graves LM, Skinner MP, Krebs EG, Ross R. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci 1995; 766: 416-30.
44. Hase S, Nakazawa S, Tsukamoto Y, Segawa K. Effects of prednisolone and human epidermal growth factor on angiogenesis in granulation tissue of gastric ulcer induced by acetic acid. Digestion 1989; 42: 135-42.
45. Pai R, Szabo IL, Giap AQ, Kawanaka H, Tarnawski AS. Nonsteroidal anti- inflammatory drugs inhibit re-epithelialization of wounded gastric monolayers by interfering with actin, Src, FAK, and tensin signaling. Life Sci 2001; 69: 3055-71.
46. Szabo S, Folkman J, Vincze A, Sandor ZS, Gombos Z. Modulation of vascular factors by VEGF/VPF (vascular endothelial cell growth factor/vascular permeability factor) is sufficient for chronic ulcer healing and acute gastroprotection. Gastroenterology 1997; 112: A303.
47. Szabo S, Vincze A, Sandor ZS, Gombos Z. Vascular approach to gastroduodenal ulceration: new studies with endothelins and VEGF. Dig Dis Sci 1998; 43: 40S-5S.
48. Ernst H, Konturek PC, Hahn EG, Stosiek HP, Brzozowski T, Konturek SJ. Effect of local injection with basic fibroblast growth factor (BFGF) and neutralizing antibody to BFGF on gastric ulcer healing, gastric secretion, angiogenesis and gastric blood flow. J Physiol Pharmacol 2001; 52: 377-90.
49. Miura S, Tatsuguchi A, Wada K, et al. Cyclooxygenase-2- regulated vascular endothelial growth factor release in gastric fibroblasts. Am J Physiol 2004 287: G444-51.
50. Arakawa T, Watanabe T, Fukuda T, et al. Rebamipide, novel prostaglandin- inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Dig Dis Sci 1995; 40: 2469-72.